• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New Synexus board gears up for expansion through organic growth and acquisition

New Synexus board gears up for expansion through organic growth and acquisition

June 10, 2015
CenterWatch Staff

Following the completion of the management buyout of Synexus, the new board confirms its intention to expand the footprint of the company through organic growth and acquisition. Synexus, a multi-national company dedicated to the recruitment and running of clinical trials at its own research centers across the globe, intends to become a major player in the U.S., continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.

The new board members of Synexus are chairman Charles Woler and non-executives Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham. Christophe Berthoux, CEO of Synexus, and Paul Chambers, financial director of Synexus, will remain on the board.

Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and lately in smaller, earlier stage companies—positions included chairman and CEO of Roche France, chairman of SmithKline Beecham’s European pharmaceutical business and CEO of Cadus Pharmaceuticals.

Harrild is the head of U.K. for the Direct Lending team of BlueBay Asset Management, and was part of BlueBay’s Direct Lending business from its inception in 2011.

Evans has experience in pharma and in the CRO sector, including being managing director of Novo Nordisk U.K., managing director of Takeda Pharmaceuticals U.K., and after joining Quintiles he rose to become president of Europe. He also is chairman of Western Sussex Hospitals NHS Trust.

Gould is director and office head of LDC Manchester and has over 20 years of experience from the advisory arena, private equity, as well as being the finance director of two private equity backed businesses.

Braham is the investment director at LDC Manchester—part of the Lloyds Group—and has over 17 years’ experience in advisory, banking, restructuring and private equity.

Professor Trevor Jones, CBE, will continue to chair the Synexus scientific advisory board.

Since 2007 Synexus has expanded its international network from 13 to 25 dedicated research centers across eight countries. At any one time these centers are involved in more than 200 trials with 14,000 patients. Recent expansion has included new site openings in Hexham in the U.K. (a pioneering partnership with the NHS), Bochum in Germany, Bucharest in Romania, Poznan in Poland and Sofia in Bulgaria. Synexus also acquired a site near Cape Town in South Africa. This expansion has increased its access to more than 68 million potential patients. In addition it has a network of 25 complementary affiliate sites which further extends Synexus’ reach.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing